WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 10, 2017-- Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine’s 2017 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 17 development candidates against 14 different molecular targets.
“It is an honor to be recognized as one of the World’s Most Innovative Companies by Forbes year-after-year,” said Hervé Hoppenot, Incyte’s Chief Executive Officer. “At Incyte, innovation is in our DNA. We push ourselves every day to be at the forefront of advancing science as we research and develop treatments that will positively impact the lives of patients around the world.”
Forbes’ ranking is based on the companies’ “innovation premium,” and only includes industries that are known to invest in innovation and businesses that have at least seven years of financial data and a market value greater than $10 billion.
To view the complete list, visit http://www.forbes.com/innovative-companies/list/.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170810005610/en/
Source: Incyte Corporation
Incyte Corporation
Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com
